Reimbursed Care Access in South Africa

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (intranasal Spravato) has been reported as released/available in South Africa for treatment‑resistant depression through registered/restricted clinical pathways and specialist services; its use is described as part of levelled care for Treatment‑Resistant Depression with defined psychiatrist‑led pathways. Clinical societies in South Africa (e.g., South African Society of Psychiatrists) have issued guidance on esketamine use and the role of intranasal esketamine and IV ketamine in TRD care pathways. #.

Regulatory framework: medicines and controlled substances in South Africa are regulated under the Medicines and Related Substances Act (No. 101 of 1965) and administered by the South African Health Products Regulatory Authority (SAHPRA). Special controls apply to higher‑schedule medicines requiring prescriptions and in some cases restricted distribution, and SAHPRA maintains product registration and permit systems for Schedule 5/6/7 substances. Providers and clinics offering esketamine are expected to operate within SAHPRA registration/approval and professional regulatory oversight. # #.

Reimbursement and access: esketamine is not part of universal public reimbursement as a routinely funded medicine in the public sector; access is delivered primarily through specialist private sector programs or registered products with restricted programmes. Private medical aid (insurance) coverage is variable and typically requires demonstration of treatment‑resistant depression (failure of multiple prior antidepressant trials), specialist psychiatric initiation, and adherence to monitoring/safety programmes — coverage decisions are insurer‑specific and often subject to pre‑authorisation. Public sector routine funding for esketamine is not publicly documented as an established, universally funded option; access in public hospitals would depend on local formularies, exceptional approvals, and SAHPRA registration/section‑36 or permit mechanisms. # #.

Ketamine is a legally‑available registered anaesthetic and analgesic in South Africa (controlled under the national medicines scheduling framework) and is routinely used in clinical anaesthesia, emergency medicine and pain services; it is also used off‑label in specialist psychiatric settings for treatment‑resistant depression and acute suicidality under psychiatrist‑led care pathways. The Medicines and Related Substances Act and its scheduling provisions govern its prescription and repeat dispensing rules (Schedule controls such as limits on repeat prescriptions and special handling/recording obligations). #.

Clinical practice and guidance: South African psychiatric and anaesthesia professional bodies have issued position/guidance documents emphasising that ketamine for depression should be delivered in higher‑level care (specialist/psychiatrist‑led pathways), with IV administration by anaesthetists or anaesthetically‑trained clinicians following local protocols; the South African Society of Psychiatrists (SASOP) explicitly recommends specialist oversight and adherence to safety/monitoring standards for IV ketamine and intranasal esketamine for TRD. These guidance documents describe pathway levels (level 2–7 care), contraindications, and the need for multidisciplinary involvement. #.

Reimbursement and access: ketamine used as an anaesthetic or analgesic is part of routine hospital formularies and is reimbursed in the context of standard medical care (public and private) when used for licensed indications (anaesthesia, analgesia). Ketamine for psychiatric, off‑label indications (e.g., IV ketamine infusions for TRD) is largely provided in private specialist clinics and hospital units; reimbursement by private medical aids is variable and usually requires pre‑authorisation, specialist referral, and documentation of treatment‑resistant illness. Public sector access for psychiatric ketamine is limited and generally not a standard, reimbursed public mental‑health intervention—availability depends on local provincial formulary decisions, specialist services, and exceptional approvals (e.g., permits) under SA regulatory frameworks. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (including ayahuasca) are treated under the same controlled‑substance rules and are not an authorised, reimbursed medical therapy. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Ibogaine occupies a legally and clinically contested position in South Africa. There are reports of private clinics and practitioners using ibogaine for addiction treatment, and some sources describe ibogaine as being treated as a medication under strict medical oversight in certain contexts; however its use is linked to legal risk, safety concerns, and criminal investigations when administered outside regulated settings. High‑profile adverse events and prosecutions have occurred in South Africa related to unregulated ibogaine administration. Operational access is effectively limited to specialised private providers or research/permit pathways rather than routine, reimbursed public therapy. # #.

Regulatory note: any clinical use of ibogaine outside registered clinical trials would require permits/authorisation under SA medicine and controlled‑substance statutes and professional regulatory oversight; because of safety concerns (cardiotoxicity and deaths reported), SA professional and regulatory authorities treat such use as high risk and not part of standard reimbursed care. #.

Preparations containing DMT (ayahuasca) are controlled under South African drug laws and there is no authorised medical or sacramental exemption in national law for routine use; therefore ayahuasca is not an authorised reimbursed therapy and is limited to informal, unregulated or religious/ceremonial contexts which carry legal risk. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, manufacture or supply is controlled and not part of reimbursed medical care. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (This category includes 2C family analogues such as 2C‑B, 2C‑I etc.) #